← Back to Search

Technology-Enabled Care Model for Post-COVID Syndrome (LC&FIRP Trial)

N/A
Waitlist Available
Led By Christian Ramers, MD
Research Sponsored by Family Health Centers of San Diego
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up during 37 months of follow-up
Awards & highlights
No Placebo-Only Group

Summary

This trial is testing a program to help people with long term effects of COVID and other fatigue-inducing illnesses. The goal is to see if the program is effective and how well it works.

Who is the study for?
This trial is for licensed primary care physicians, physician assistants, or nurse practitioners at the Family Health Center of San Diego who treat patients with long-lasting symptoms and reduced quality of life due to Long COVID, Chronic Fatigue Syndrome (ME/CFS), or other post-infectious fatiguing illnesses. Participants must be willing to engage in a teleECHO program.
What is being tested?
The study tests the effectiveness of a multi-disciplinary team-based care model via teleECHO for managing complex cases related to Long COVID and similar conditions. It aims to improve clinical outcomes and assess the feasibility and sustainability of such programs in community healthcare settings.
What are the potential side effects?
Since this trial focuses on a care model rather than medication, traditional side effects are not applicable. However, there may be indirect effects on clinicians' practice patterns or patient satisfaction that will be monitored.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~during 37 months of follow-up
This trial's timeline: 3 weeks for screening, Varies for treatment, and during 37 months of follow-up for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Patient-Reported Outcomes Measurement Information System (PROMIS)-29
Secondary study objectives
2-minute step test
30 sec sit to stand test
Balance tasks
+35 more
Other study objectives
Application of specialist recommendations
Average consultation duration
Best part of session
+78 more

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: InterventionExperimental Treatment1 Intervention
The Intervention arm participates in weekly teleECHO sessions with monthly interactive webinars and quarterly short courses.
Group II: ControlActive Control1 Intervention
The Control arm participates in monthly interactive webinars and quarterly short courses. Monthly interactive webinars will offer brief didactic presentations by SMEs, examples of models of care, and a facilitated Q\&A. These webinars will be convened to rapidly disseminate findings and emerging best practices to a large-scale, national audience. Quarterly short courses will be developed to summarize key findings from past weekly teleECHO sessions. These quarterly short courses will be formatted as a learning module with the use of presentation slides and videos online that are accessible asynchronously.

Find a Location

Who is running the clinical trial?

Family Health Centers of San DiegoLead Sponsor
7 Previous Clinical Trials
14,753 Total Patients Enrolled
Christian Ramers, MDPrincipal InvestigatorFamily Health Centers of San Diego
1 Previous Clinical Trials
2 Total Patients Enrolled
Job Godino, PhDPrincipal InvestigatorFamily Health Centers of San Diego

Media Library

Extension for Community Healthcare Outcomes Clinical Trial Eligibility Overview. Trial Name: NCT05167227 — N/A
Chronic Fatigue Syndrome Research Study Groups: Control, Intervention
Chronic Fatigue Syndrome Clinical Trial 2023: Extension for Community Healthcare Outcomes Highlights & Side Effects. Trial Name: NCT05167227 — N/A
Extension for Community Healthcare Outcomes 2023 Treatment Timeline for Medical Study. Trial Name: NCT05167227 — N/A
~5 spots leftby Nov 2025